Patents by Inventor Robin D. Clark

Robin D. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140179671
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: September 12, 2013
    Publication date: June 26, 2014
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Patent number: 8557839
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: October 15, 2013
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Patent number: 8324203
    Abstract: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: December 4, 2012
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul Blaney, Christopher Hurley, Hazel Hunt, David Clark, Karen Williams
  • Publication number: 20120225856
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: May 21, 2012
    Publication date: September 6, 2012
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Patent number: 8173664
    Abstract: The present invention provides a class of modified pyrimidine compounds, compositions and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: May 8, 2012
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicolas C. Ray, Karen Williams, Peter H. Crackett, Gwen Hickin, David A. Clark
  • Publication number: 20110166110
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: March 11, 2011
    Publication date: July 7, 2011
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Patent number: 7928237
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: April 19, 2011
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Publication number: 20100120759
    Abstract: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: January 21, 2010
    Publication date: May 13, 2010
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. CLARK, Nicholas C. RAY, Paul BLANEY, Christopher HURLEY, Hazel HUNT, David CLARK, Karen WILLIAMS
  • Patent number: 7678813
    Abstract: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: March 16, 2010
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul Blaney, Christopher Hurley, Hazel Hunt, David Clark, Karen Williams
  • Publication number: 20090275600
    Abstract: The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: July 8, 2009
    Publication date: November 5, 2009
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicolas C. Ray, Karen Williams, Peter H. Cracket, Gwen Hickin, David A. Clark
  • Patent number: 7576076
    Abstract: The present invention provides a compound having the formula: wherein, n and m are 1; X1 and X2 are O; R1 is a member selected from unsubstituted phenyl and substituted phenyl; R2 is a member selected from hydrogen, —CN, —OR2A, -L2A—C(O)R2B, -L2B—S(O)2R2C; R3 is a member selected from unsubstituted benzyl and substituted benzyl; R4 is a member selected from hydrogen and substituted or unsubstituted alkyl, wherein if R4 is methyl, then -L1-R1 is not benzyl or —C(O)—O—CH2—CH3; and L1 is a bond; and compositions and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: August 18, 2009
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicolas C. Ray, Karen Williams, Peter H. Crackett, Gwen Hickin, David A. Clark
  • Patent number: 5726197
    Abstract: Compounds of the Formula: ##STR1## wherein: R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halo, optionally substituted phenyl, amino, nitro or trifluoromethyl; andX is --NH--, --O-- or --S--;and the pharmaceutically acceptable salts thereof exhibit high affinity and selectivity for imidazoline receptors, and are are particularly useful for modification of the female reproductive cycle.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: March 10, 1998
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Michael Spedding
  • Patent number: 5527918
    Abstract: The present invention relates to processes for preparing 1-butyl-2-[2'-(2H-tetrasol-5-yl)biphenyl-4-ylmethyl]-1H-indole-3-carboxyli c acid and to intermediates useful in such processes. The present invention also relates to a process for deprotecting compounds containing a protected 2H-tetrasolyl group, which process comprises reacting a the protected compound with a Lewis acid in the presence of a thiol.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: June 18, 1996
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Lawrence E. Fisher, Lee A. Flippin, Michael G. Martin, Stephen R. Stabler
  • Patent number: 5492914
    Abstract: This invention relates to 2-(1'-azabicyclo[2.2.2]oct-3'S-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[de ]isoquinolin-1-one and 2-(1'-azabicyclo[2.2.2]oct-3'S-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1H-ben z[de]isoquinolin-1-one and their individual stereoisomers and uses and the processes for their making.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: February 20, 1996
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Jacob Berger, Robin D. Clark, Paul E. Weller, Douglas L. Wren
  • Patent number: 5491148
    Abstract: 5-HT.sub.3 receptor antagonist compounds of Formula I: ##STR1## in which X and Y are independently selected from hydrogen, halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, aminocarbonyl, (lower alkyl)amino, di(lower alkyl)amino and (lower alkanoyl)amino;R.sup.1 is hydrogen, lower alkyl, phenyl or halogen;R.sup.
    Type: Grant
    Filed: April 26, 1991
    Date of Patent: February 13, 1996
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Jacob Berger, Robin D. Clark
  • Patent number: 5446121
    Abstract: The present invention relates to processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-indole-3-carboxyli c acid and to intermediates useful in such processes. The present invention also relates to a process for deprotecting compounds containing a protected 2H-tetrazolyl group, which process comprises reacting a the protected compound with a Lewis acid in the presence of a thiol.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: August 29, 1995
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Lawrence E. Fisher, Lee A. Flippin, Michael G. Martin, Stephen R. Stabler
  • Patent number: 5412102
    Abstract: The present invention relates to processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-indole-3-carboxyli c acid and to intermediates useful in such processes. The present invention also relates to a process for deprotecting compounds containing a protected 2H-tetrazolyl group, which process comprises reacting a the protected compound with a Lewis acid in the presence of a thiol.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: May 2, 1995
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Lawrence E. Fisher, Lee A. Flippin, Michael G. Martin, Stephen R. Stabler
  • Patent number: 5380739
    Abstract: Compounds of the Formula (I), (II), or (III): ##STR1## wherein the variables are as defined in the specification and the pharmaceutically acceptable salts thereof, exhibit useful pharmacological properties, and are particularly useful as angiotensin II antagonists.
    Type: Grant
    Filed: February 4, 1993
    Date of Patent: January 10, 1995
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, David E. Clarke, Lawrence E. Fisher, Alam Jahangir
  • Patent number: 5229387
    Abstract: Compounds of the formula ##STR1## wherein: m is an integer of 1-6;n is an integer of 1 or 2;X and Y are independently hydrogen; hydroxy; lower alkyl; lower alkoxy; or halo; or X and Y when adjacent and taken together are methylenedioxy or ethylene-1,2-dioxy;R is ##STR2## wherein: R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl, or when taken together with the carbon to which they are attached are cycloalkyl;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halo; and ##STR3## and pharmaceutically acceptable acid addition salts thereof. The compounds and salts exhibit useful pharmacological properties, including selective .alpha..sub.2 -adrenoceptor antagonist properties and 5-HT.sub.1A receptor partial agonist properties, and are particularly useful for the treatment of sexual dysfunction, depression and anxiety.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: July 20, 1993
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Brian H. Vickery, Mike Spedding
  • Patent number: 5212195
    Abstract: Compound of the Formula (I), (II), or (III): ##STR1## wherein: R.sup.1 is lower alkyl or 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl;R.sup.2 is lower alkyl when R.sup.1 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl; or R.sup.2 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl when R.sup.1 is lower alkyl;R.sup.3 is hydrogen or lower alkyl;X is hydrogen, lower alkyl, halogen, --C(O)CF.sub.3, --CO.sub.2 R.sup.4, or --C(O)NR.sup.5 R.sup.6 ;Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, or --CO.sub.2 R.sup.4 ;Z is hydrogen, lower alkyl, lower alkoxy, or halogen; with the proviso that Y and Z cannot be attached to the nitrogen atom in Formula (II); whereinR.sup.4 is hydrogen or lower alkyl;R.sup.5 is hydrogen or lower alkyl;R.sup.6 is hydrogen or lower alkyl; orR.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a heterocycle;and pharmaceutically acceptable salts thereof, exhibit useful pharmacological properties, and are particularly useful as angiotensin II antagonists.
    Type: Grant
    Filed: May 13, 1992
    Date of Patent: May 18, 1993
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, David E. Clarke, Lawrence E. Fisher, Alam Jahangir